Aemetis Reports Q2 2025 Financials: Revenue Drop, Increased Losses, but Cost Control Improvements

Aemetis, Inc. (NASDAQ: AMTX) reported its Q2 2025 quarterly results with key insights on financial performance and operational developments.

Financial Highlights:

• Revenue: $52.2 million in Q2 2025, down 21.5% from $66.6 million in Q2 2024.
• Gross Loss: $(3.4) million in Q2 2025, compared to $(1.8) million in Q2 2024.
• Operating Loss: $(10.7) million in Q2 2025, improved from $(13.6) million in Q2 2024.
• Net Loss: $(23.4) million in Q2 2025 vs. $(29.2) million in Q2 2024.
• Basic Loss per Share: $(0.41) in Q2 2025 compared to $(0.66) in Q2 2024.

Positive Aspects:

• Selling, general, and administrative expenses decreased by 38% to $7.3 million from $11.8 million year-over-year, indicating tighter cost control.
• Revenue from the California Dairy Renewable Natural Gas segment increased by 90.9% to $3.1 million in Q2 2025, driven by higher methane sales.
• Total cash and cash equivalents rose to $1.6 million from $0.9 million, improving liquidity position slightly.

Negative Aspects:

• Significantly decreased revenue from the India Biodiesel segment, plummeting 52.1% to $11.9 million due to delays in tender contracts.
• Total liabilities increased to $344.2 million from $338.1 million, highlighting ongoing debt challenges.
• Current ratio worsened to 0.06 from 0.31, indicating severe liquidity issues.

Summary of Key Statistics:

• Revenue by Segment: - California Ethanol: $37.3 million - California Dairy RNG: $3.1 million - India Biodiesel: $11.9 million
• Cost of Goods Sold: $55.6 million in Q2 2025.
• Interest Expense: $11.2 million in Q2 2025, increased from $9.9 million in Q2 2024.
• Negative Operating Cash Flow: $(5.6) million for the six months ended June 30, 2025.

Aemetis continues to operate under significant financial pressure, with considerable debt and reduced revenues in key markets, particularly biodiesel. However, improvements in managing operational expenses and growth in renewable natural gas sales may present a pathway for recovery in the upcoming quarters.